PMID- 31486206
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20221005
IS  - 1744-9987 (Electronic)
IS  - 1744-9979 (Print)
IS  - 1744-9979 (Linking)
VI  - 24
IP  - 3
DP  - 2020 Jun
TI  - Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary 
      Hyperparathyroidism.
PG  - 248-257
LID - 10.1111/1744-9987.13434 [doi]
AB  - Patients with chronic kidney disease often develop secondary hyperparathyroidism 
      (SHPT), marked by high levels of circulating parathyroid hormone (PTH) and 
      increased risk of morbidity and mortality. Patients with SHPT are treated with a 
      therapeutic combination that commonly includes calcimimetics, which have recently 
      become popular in clinical settings, and other agents such as vitamin D 
      preparations. Calcimimetics are a drug class that reduces PTH levels by targeting 
      the calcium-sensing receptor. Cinacalcet, a representative calcimimetic, is 
      widely used; however, a high incidence of upper gastrointestinal (GI) 
      tract-related adverse events (AEs) can result in insufficient dosage and poor 
      long-term compliance. The newly approved evocalcet has equivalent efficacy to 
      cinacalcet at a lower clinical dose, with improved bioavailability, fewer upper 
      GI tract-related AEs, and fewer safety concerns. This review gives an overview of 
      calcimimetic agents, with a special focus on evocalcet, and describes the 
      clinical advantages of evocalcet in the treatment of dialysis patients with SHPT.
CI  - (c) 2019 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & 
      Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese 
      Society for Apheresis, and Japanese Society for Dialysis Therapy.
FAU - Akizawa, Tadao
AU  - Akizawa T
AD  - Division of Nephrology, Department of Medicine, Showa University School of 
      Medicine, Tokyo, Japan.
FAU - Ikejiri, Kazuaki
AU  - Ikejiri K
AUID- ORCID: 0000-0001-6096-4723
AD  - R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
FAU - Kondo, Yuichiro
AU  - Kondo Y
AD  - R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
FAU - Endo, Yuichi
AU  - Endo Y
AD  - R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan.
FAU - Fukagawa, Masafumi
AU  - Fukagawa M
AD  - Division of Nephrology, Endocrinology and Metabolism, Tokai University School of 
      Medicine, Kanagawa, Japan.
LA  - eng
GR  - Kyowa Hakko Kirin Co., Ltd./
PT  - Journal Article
PT  - Review
DEP - 20191023
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - 0 (Calcimimetic Agents)
RN  - 0 (Naphthalenes)
RN  - 0 (Pyrrolidines)
RN  - 0 (Receptors, Calcium-Sensing)
RN  - E58MLH082P (evocalcet)
SB  - IM
MH  - Calcimimetic Agents/pharmacology
MH  - Drug Discovery
MH  - Humans
MH  - *Hyperparathyroidism, Secondary/drug therapy/etiology
MH  - Naphthalenes/*pharmacology
MH  - Pyrrolidines/*pharmacology
MH  - Receptors, Calcium-Sensing/antagonists & inhibitors
MH  - Renal Dialysis/methods
MH  - *Renal Insufficiency, Chronic/complications/metabolism/therapy
MH  - Treatment Outcome
PMC - PMC7317959
OTO - NOTNLM
OT  - Calcimimetic agents
OT  - Calcium-sensing receptor
OT  - Dialysis
OT  - Parathyroid hormone
OT  - Secondary hyperparathyroidism
EDAT- 2019/09/06 06:00
MHDA- 2021/12/15 06:00
PMCR- 2020/06/26
CRDT- 2019/09/06 06:00
PHST- 2019/08/26 00:00 [revised]
PHST- 2019/05/30 00:00 [received]
PHST- 2019/08/30 00:00 [accepted]
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2019/09/06 06:00 [entrez]
PHST- 2020/06/26 00:00 [pmc-release]
AID - TAP13434 [pii]
AID - 10.1111/1744-9987.13434 [doi]
PST - ppublish
SO  - Ther Apher Dial. 2020 Jun;24(3):248-257. doi: 10.1111/1744-9987.13434. Epub 2019 
      Oct 23.